Scientists develop new drug for virus affecting lakhs each year, offers 99.9% protection with two injections, it is priced at Rs…
Despite decades of studies on virus treatment, more than one million people are infected with human immune failure virus (HIV) each year. Continue reading to know more.
The side effects reported by the participants were injection zone reactions, headaches and nausea.
Despite decades of studies on virus treatment, more than one million people are infected with human immune failure virus (HIV) each year. However, in a major breakthrough, the United States Food and Drug Administration (FDA) approved Lenacapavir, a new medicine, a long -acting drug, which offers almost full protection against HIV, which causes acquired immune insufficiency syndrome (AIDS). So far, most HIV treatment has needed daily pills, which is a routine to follow many.
What did the company say?
“This is a historical day in the struggle against HIV for decades. Yeztugo is one of the most important scientific breakthroughs of our time, and offers a real opportunity to help end the HIV epidemic.” “This is a drug that should only be given twice a year and shows remarkable results in clinical studies, ie HIV prevention.
What are the ones reported in clinical studies?
Lenacapavir, marketed under the Yaztugo brand, has shown that clinical studies reduced the risk of HIV transmission over 99.9 percent in adults and adolescents. The company conducted two major clinical studies for the drug. First, it resulted in a 100 percent decrease in infections, containing more than 2,000 women in sub -Sahara Africa. In the second hearing, only two infections were reported to indicate the prevention rate of 99.9 percent, including more than 2,000 men and gender-evolving people.
The side effects reported by the participants were injection zone reactions, headaches and nausea.
How much will it cost?
The results of both essays were published in New England Journal of Medicine and named the Science Magazine Lenacapavir.
However, the drug is expected to come with a heavy price tag. Although Gilead has not yet published a price for Yeztugo, analysts say that the US launch may be more than 25,000 USD or 21 Lakh per year, according to today’s exchange rate. Activists around the world appeal to Gilead to largely cut the price to help end the HIV epidemic.
